U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C16H19ClO2
Molecular Weight 278.774
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLIDANAC

SMILES

OC(=O)C1CCC2=CC(C3CCCCC3)=C(Cl)C=C12

InChI

InChIKey=OIRAEJWYWSAQNG-UHFFFAOYSA-N
InChI=1S/C16H19ClO2/c17-15-9-13-11(6-7-12(13)16(18)19)8-14(15)10-4-2-1-3-5-10/h8-10,12H,1-7H2,(H,18,19)

HIDE SMILES / InChI

Molecular Formula C16H19ClO2
Molecular Weight 278.774
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/6114148

Clidanac is an anti-inflammatory agent developed in Japan for the treatment of rheumatoid arthritis. The drug is mixture of two isomers, d- and l-, and the d-form is more active than the l-form. Therapeutic effect of clidanac is mediated by the inhibition of prostaglandin biosynthesis.

Originator

Curator's Comment: # Takeda Pharmaceutical

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q9H7Z7
Gene ID: 80142.0
Gene Symbol: PTGES2
Target Organism: Homo sapiens (Human)
2.7 µM [IC50]
Target ID: Q8TBF2|||J3KQD0
Gene ID: 127281.0
Gene Symbol: FAM213B
Target Organism: Homo sapiens (Human)
2.9 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The effect of clidanac, a potent anti-inflammatory drug, on mitochondrial respiration: a consideration on the uncoupling activity of optical enantiomers.
1984-09
[Influence of indomethacin and clidanac on the blood pressure lowering effect of beta-blockers].
1983-01
Inhibition of prostaglandin biosynthesis by clidanac and related compounds: structural and conformational requirements for PG synthetase inhibition.
1981-01
Biological activities of optical isomers of 6-chloro-5-cyclohexylindan-1-carboxylic acid (TAI-284: anti-inflammatory agent).
1974-10
Biological activities of metabolites of 6-chloro-5-cyclohexylindan-1-carboxylic acid (TAI-284: anti-inflammatory agent).
1974-10
Metabolism of 6-chloro-5-cyclohexylindane-1-carboxylic acid (TAI-284), a new non-steroidal anti-inflammatory agent. I. Absorption, distribution and excretion in rats.
1973-10
Anti-inflammatory, analgesic and antipyretic activities of 6-chloro-5-cyclohexylindan-1-carboxylic acid (TAI-284).
1971-10
6-chloro-5-cyclohexylindan-1-carboxylic acid (TAI-284), a new antiinflammatory agent.
1971-03
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
Inhibitory effect of clidanac on ADP-induced rat platelet aggregation was tested in vitro. At concentrations 1*10(-3), 5*10(-4), 1*10(-4) M the drug produced 76, 16 and 0% of inhibition. At 10(-4) M the drug caused 61% of inhibition of the heat-induced erythrocyte lysis.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:16:59 GMT 2025
Edited
by admin
on Mon Mar 31 18:16:59 GMT 2025
Record UNII
UA6HM01WAK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BRITAI
Preferred Name English
CLIDANAC
INN   JAN   MI   WHO-DD  
INN  
Official Name English
(±)-CLIDANAC
Common Name English
(±)-TAI-284
Common Name English
clidanac [INN]
Common Name English
CLIDANAC [JAN]
Common Name English
CLIDANAC [MI]
Common Name English
(±)-6-CHLORO-5-CYCLOHEXYLINDANE-1-CARBOXYLIC ACID
Systematic Name English
CLIDANAC, (±)-
Common Name English
TAI-284
Code English
INDANAL
Systematic Name English
6-CHLORO-5-CYCLOHEXYL-1-INDANCARBOXYLIC ACID
Systematic Name English
Clidanac [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C257
Created by admin on Mon Mar 31 18:16:59 GMT 2025 , Edited by admin on Mon Mar 31 18:16:59 GMT 2025
Code System Code Type Description
MESH
C059095
Created by admin on Mon Mar 31 18:16:59 GMT 2025 , Edited by admin on Mon Mar 31 18:16:59 GMT 2025
PRIMARY
PUBCHEM
120108
Created by admin on Mon Mar 31 18:16:59 GMT 2025 , Edited by admin on Mon Mar 31 18:16:59 GMT 2025
PRIMARY
CAS
28968-07-2
Created by admin on Mon Mar 31 18:16:59 GMT 2025 , Edited by admin on Mon Mar 31 18:16:59 GMT 2025
SUPERSEDED
NCI_THESAURUS
C77342
Created by admin on Mon Mar 31 18:16:59 GMT 2025 , Edited by admin on Mon Mar 31 18:16:59 GMT 2025
PRIMARY
MERCK INDEX
m654
Created by admin on Mon Mar 31 18:16:59 GMT 2025 , Edited by admin on Mon Mar 31 18:16:59 GMT 2025
PRIMARY Merck Index
CAS
34148-01-1
Created by admin on Mon Mar 31 18:16:59 GMT 2025 , Edited by admin on Mon Mar 31 18:16:59 GMT 2025
PRIMARY
SMS_ID
100000084273
Created by admin on Mon Mar 31 18:16:59 GMT 2025 , Edited by admin on Mon Mar 31 18:16:59 GMT 2025
PRIMARY
FDA UNII
UA6HM01WAK
Created by admin on Mon Mar 31 18:16:59 GMT 2025 , Edited by admin on Mon Mar 31 18:16:59 GMT 2025
PRIMARY
EVMPD
SUB06659MIG
Created by admin on Mon Mar 31 18:16:59 GMT 2025 , Edited by admin on Mon Mar 31 18:16:59 GMT 2025
PRIMARY
INN
4357
Created by admin on Mon Mar 31 18:16:59 GMT 2025 , Edited by admin on Mon Mar 31 18:16:59 GMT 2025
PRIMARY
DRUG CENTRAL
675
Created by admin on Mon Mar 31 18:16:59 GMT 2025 , Edited by admin on Mon Mar 31 18:16:59 GMT 2025
PRIMARY
ChEMBL
CHEMBL130393
Created by admin on Mon Mar 31 18:16:59 GMT 2025 , Edited by admin on Mon Mar 31 18:16:59 GMT 2025
PRIMARY
EPA CompTox
DTXSID2022834
Created by admin on Mon Mar 31 18:16:59 GMT 2025 , Edited by admin on Mon Mar 31 18:16:59 GMT 2025
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY